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Background
Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the
t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in
acute promyelocytic leukemia is still a controversial matter. 
Design and Methods
Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia
enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence,
characteristics, and outcome of patients with acute promyelocytic leukemia with and without
additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus
anthracycline monochemotherapy for induction and consolidation.
Results
Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was
the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chro-
mosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts
(P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional
abnormalities. No significant association with FLT3/ITD or other clinicopathological character-
istics was demonstrated. Patients with and without additional chromosomal abnormalities had
similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that
additional chromosomal abnormalities were associated with a lower relapse-free survival in
the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal
abnormalities overall nor any specific abnormality was identified as an independent risk factor
for relapse in multivariate analysis. 
Conclusions
The lack of independent prognostic value of additional chromosomal abnormalities in acute
promyelocytic leukemia does not support the use of alternative therapeutic strategies when
such abnormalities are found. 
Key words: acute promyelocytic leukemia, additional chromosomal abnormalities,
prognostic factors, all-trans retinoic acid, anthracycline.
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Introduction
Cytogenetics is the most powerful single prognostic fac-
tor for outcome in acute myeloid leukemia1-3 and the most
useful guide available for stratification and planning post-
remission treatment in this disease. The t(15;17), character-
izing the acute promyelocytic form of acute myeloid
leukemia, is considered to be a favorable cytogenetic fea-
ture. However, the prognostic significance of additional
cytogenetic abnormalities (ACA) in acute promyelocytic
leukemia (APL) has remained a matter of debate. 
During the 1990s, some studies suggested a relationship
between ACA and outcome in APL.4,5 However, these
studies were retrospective and performed in small series of
patients mostly treated with chemotherapy alone. More
recently, three studies undertaken in patients with APL
managed with state-of-the-art treatments, that is, a simul-
taneous combination of all-trans retinoic acid (ATRA) with
anthracycline-based chemotherapy, have yielded conflict-
ing results with regard to the impact of ACA on prognosis.
In two large studies ACA were not found to have an
impact on prognosis,6,7 while, in the third study, patients
with ACA had a higher death rate during induction thera-
py compared with patients exhibiting the t(15;17) alone.8
Although none of these studies demonstrated that ACA in
APL have a significant impact on the risk of relapse, physi-
cians may be tempted to modify the planned treatment
based on the presence of these abnormalities, extrapolating
strategies used for the management of other subtypes of
acute myeloid leukemia.
In order to clarify the role of ACA in APL patients treat-
ed with modern treatments, we report here the character-
istics, outcome and prognostic value of cytogenetics in a
large cohort of successfully karyotyped patients with a
long follow-up who were enrolled in two successive stud-
ies carried out by the Spanish Programa de Estudio y
Tratamiento de las Hemopatías Malignas (PETHEMA) group
(studies LPA96 and LPA99).
Design and Methods
Patients and eligibility
Between November 1996 and June 2005, a total of 739 patients
with de novo, genetically confirmed APL were enrolled into two
consecutive trials, LPA96 and LPA99. The eligibility criteria and
protocols of these studies have been reported elsewhere.9-11
Informed consent to participation in the studies was obtained
from all patients, in accordance with the Declaration of Helsinki.
The protocol was approved by the Research Ethics Board of each
participating hospital.
Diagnosis
In addition to the morphological and cytochemical criteria used
by the French-American-British classification and routine
immunophenotyping, the diagnosis of APL was genetically con-
firmed in all cases by demonstration of the PML/RARA hybrid
gene and/or the chromosomal translocation t(15;17)(q22;q21).
Immunophenotypic and cytogenetic analyses were systematical-
ly performed at presentation only. For the purpose of rapid diag-
nosis, an immunohistochemical analysis of PML protein distribu-
tion was performed, using the monoclonal antibody PG-M3,12 in
a subgroup of patients.
Cytogenetics and fluorescence in situ hybridization
Bone marrow samples for cytogenetic analysis were processed
after short-term culture (24 or 48 h) following standard proce-
dures. The chromosomes were stained by G-banding and the
karyotypes reported according to International System for
Human Cytogenetic Nomenclature (ISCN, 1995) recommenda-
tions.13 Whenever possible at least 20 metaphases were analyzed
in each case. Cases were considered normal diploid if no clonal
abnormalities were detected in a minimum of 20 mitotic cells. In
most of the patients with apparently normal karyotype and
PML/RARA rearrangement demonstrated by reverse transcriptase-
polymerase chain reaction (RT-PCR), fluorescence in situ
hybridization (FISH) studies were additionally carried out in
metaphase and interphase nuclei. Two-color FISH was performed
using a PML/RARA translocation probe (Abbott, Wiesbaden,
Germany).
The majority of cytogenetic analyses were performed at refer-
ence laboratories. The original cytogenetics reports were request-
ed from the centers for central review. Appropriate karyotype
nomenclature (ISCN 1995) was centrally reviewed by two of the
authors (JC, JMH). For the purposes of this study, patients with a
normal karyotype with the PML/RARA fusion demonstrated by
either RT-PCR or FISH, were considered as having APL without
ACA.4,14 
Reverse transcriptase–polymerase chain reaction 
studies
The details on processing bone marrow samples for RNA
extraction and on the RT-PCR protocols for PML/RARA amplifica-
tion used by the participating laboratories have been described
elsewhere.15,16
Treatment
The induction regimen consisted of oral ATRA (45 mg/m2/day),
divided into two daily doses, which was maintained until com-
plete remission, and intravenous idarubicin (12 mg/m2/day) on
days 2, 4, 6, and 8. For patients 20 years of age or younger, the
ATRA dose was adjusted to 25 mg/m2/day. From November 1999,
the idarubicin on day 8 was omitted for patients older than 70
years. Patients in complete remission received three monthly con-
solidation courses. The first course consisted of idarubicin (5
mg/m2/day for 4 days), the second of mitoxantrone (10
mg/m2/day for 5 days), and the third of idarubicin (12 mg/m2/day
for 1 day). From November 1999 (LPA99 study), intermediate- and
high-risk patients, as previously defined,17 received ATRA (45
mg/m2/day for 15 days) combined with the three chemotherapy
courses;10,11 those based on idarubicin were slightly reinforced by
increasing the dose in the first course to 7 mg/m2/day and by
administering idarubicin for two consecutive days instead of one
in the third course. Patients who tested negative for PML/RARA at
the end of consolidation were started on maintenance therapy
with oral mercaptopurine (50 mg/m2/day), intramuscular
methotrexate (15 mg/m2/week), and oral ATRA (45 mg/m2/day
for 15 days every 3 months) over 2 years. Details of the support-
ive therapy have been described elsewhere.9,18
Definitions and study end-points
Response to the remission induction therapy was assessed
according to criteria recently revised by Cheson et al.19 Molecular
remission was defined as the disappearance on an ethidium bro-
mide gel of the PML/RARA-specific band visualized at diagnosis,
using an RT-PCR assay with a sensitivity level of 10-4. Molecular
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persistence was defined as PCR positivity in two consecutive
bone marrow samples collected at the end of consolidation thera-
py. Molecular relapse was defined as the reappearance of PCR-
positivity in two consecutive bone marrow samples at any time
after consolidation therapy. Risk of relapse was established at
diagnosis according to a predictive model based on each patient’s
leukocyte and platelet counts at diagnosis, as reported else-
where.17 Low-risk patients had a white cell count less than
10×109/L and a platelet count more than 40×109/L; intermediate-
risk patients had a white cell count less than 10×109/L and a
platelet count less than 40×109/L; and high-risk patients had a
white cell count equal to or more than 10×109/L. The presence of
coagulopathy was defined as a prolonged prothrombin time
and/or activated partial thromboplastin time, in addition to
hypofibrinogenemia and/or increased levels of fibrin degradation
products or D-dimers.
Statistical analysis
Differences in the distribution of variables among subsets of
patients were analyzed using χ2 and Fisher’s exact tests.
Unadjusted time-to-event analyses were performed using the
Kaplan-Meier estimate,20 and, for comparisons, log-rank tests.21
For all estimates in which the event “relapse” was considered as
an end-point, hematologic and molecular relapse, as well as
molecular persistence (PML/RARA-positive by RT-PCR at the end
of consolidation), were each considered as uncensored events.
The follow-up of the patients was updated on January 15, 2009.
The median follow-up of surviving patients was 85 months
(range, 42 to 145 months). Multivariate analysis was performed
using the Cox proportional hazards model.22 All computations
were carried out using 3D, 4F, 1L and 2L programs from the
BMDP statistical library (BMDP Statistical Software Inc, Los
Angeles, CA, USA).
Results 
Incidence and characteristics of chromosomal 
abnormalities
Between November 1996 and June 2005, a total of 739
patients with de novo, genetically confirmed APL were
enrolled into the consecutive LPA96 and LPA99 trials from
82 institutions in Spain, The Netherlands, Belgium,
Argentina, Uruguay, and the Czech Republic (see
Appendix). Cytogenetic data were not available for 244
cases because cytogenetic studies had not been performed
(n=32) or had failed (n=191), or for unknown reasons.
Failures in cytogenetic analysis were due to the absence of
metaphases (n=124) or either poor quality or insufficient
number of metaphases (n=67). All these patients were
genetically diagnosed by FISH, RT-PCR or anti-PML stain-
ing. Among the remaining 495 patients (67%), 355 (72%)
had the t(15;17) translocation as the sole chromosomal
abnormality and 140 patients (28%) had ACA; 95 of the
patients had one additional abnormality (67%) and 45 had
two or more abnormalities (33%) (Table 1). Trisomy 8 (n =
51), either alone (n = 37) or associated with other aberra-
tions (n = 14), was the most frequent abnormality (36%),
followed by other less frequent numerical and structural
aberrations listed in Table 1.
Dual color FISH studies, RT-PCR or both showed the
PML/RARA fusion gene in the 71 patients with available
karyotype in whom the t(15;17) was not detected by con-
ventional cytogenetics. In 45 of these patients the kary-
otype was normal while in the remaining 26 cases the
karyotype showed other cytogenetic changes but not the
t(15;17) (Table 1).
Cytogenetic abnormalities and disease characteristics
The main clinical and biological characteristics of
patients without an available karyotype and those with
either t(15;17) alone or t(15;17) with ACA are shown in
Table 2. Patients with ACA had significantly lower platelet
counts (P=0.02) and were, therefore, less frequently classi-
fied as at low-risk (P=0.02) compared with those without
ACA. A similar association with platelet counts and
relapse-risk score was also observed according to the num-
ber of ACA. Patients with two or more ACA had signifi-
cantly lower platelet counts (P=0.02) and were classified
less frequently as being at low-risk (P=0.02) compared
with those with a single additional chromosomal abnor-
mality. In addition, patients with ACA more frequently
had coagulopathy (P=0.03) and, although the differences
were not statistically significant, tended to be younger
(P=0.05) and more frequently had the BCR3 PML/RARA
isoform than patients with t(15;17) alone (P=0.08). The
presence of trisomy 8 was significantly associated with
more fever at diagnosis (P=0.01), coagulopathy (P=0.02),
fibrinogen levels below 170 mg/dL (P=0.02), male gender
(P=0.05), serum uric acid levels above 7 mg/dL (P=0.02),
and greater than 70% bone marrow blasts (P=0.03), and
J. Cervera et al.
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Table 1. Additional chromosomal abnormalities in patients with APL.
Number and type of Conventional Cryptic Total n. 5-year P
abnormality t(15;17) t(15;17) of patients RFS
(%) (%) (%) (%)
N. of patients 424 (100) 71 (100) 495 (100) 88
N. of chromosomal
abnormalities
Normal karyotype 0 (0) 45 (63) 45 (9) 93 0.34
t(15;17) alone 310 (73) 0 (0) 310 (63) 89
One 82 (19) 13 (18) 95 (19) 86
Two 20 (5) 5 (7) 25 (5) 83
Three or more 17 (4) 3 (4) 20 (4) 78
Numerical abnormalities 65 (15) 11(15) 76 (15)
Trisomy 8 44 (10) 7 (10) 51 (10)
Trisomy 8 alone 32 (7) 5 (7) 37 (7)
Trisomy 8 + other 12 (3) 2 (3) 14 (3)
Other numerical 21 (5) 4 (6) 25 (5)
Structural abnormalities 54 (13) 10 (14) 64 (13)
Abn(7q) 6 (1) 1 (1) 7 (1)
Abn(9q) 5 (1) 0 (0) 5 (1)
Abn(1p) 4 (1) 1 (1) 5 (1)
Abn(11q) 5 (1) 0 (0) 5 (1)
Abn(3q) 3 (1) 1 (1) 4 (1)
i(17q) 3 (1) 1 (1) 4 (1)
Abn(20q) 4 (1) 0 (0) 4 (1)
Complex variant t(15;17)* 0 (0) 4 (6) 4 (1)
Other structural 25 (6) 1 (1) 26 (5)
* complex variant t(15;17) due to a 3-way balanced translocation involving 15q22,17q21,and
another chromosome.RFS: relapse-free survival.
tended to be associated with lower platelet counts
(P=0.07). The clinicopathological characteristics of patients
with trisomy 8 alone did not differ from those of patients
with trisomy 8 plus other abnormalities. 
Influence of additional cytogenetic abnormalities on 
outcome in acute promyelocytic leukemia
Three hundred and twenty-five of the 355 patients
(91%) with the t(15;17) alone and 126 of the 140 (90%)
with ACA achieved complete remission. These rates were
Prognostic impact of additional chromosomal abnormalities in APL
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Table 2. Demographic and baseline characteristics of the study population.
Non available cytogenetics t(15;17) alone t(15;17) with other abnormalities
Characteristic Median N. (%) P# Median N. Median N. P@
(range) (range) (%) (range) (%)
Overall 244 (100) 355 (100) 140 (100)
Age, years 40 (2-81) 0.13 41 (2-83) 39 (3-73) 0.05
18 or younger 35 (14) 31 (9) 18 (13)
19-50 139 (57) 207 (58) 83 (59)
51-60 32 (13) 41 (12) 22 (16)
61-70 26 (11) 47 (13) 14 (10)
71 or older 12 (5) 29 (8) 3 (2)
Gender
Male 121 (50) 0.69 177 (50) 76 (54) 0.37
Female 123 (50) 178 (50) 64 (46)
ECOG score
0-1 172 (76) 0.69 245 (76) 95 (75) 0.84
2-3 54 (24) 84 (24) 31 (25)
WBC count, ×109/L 2.4 (0.3-164) 0.21 2.0 (0.2-460) 2.8 (0.3-210) 0.17
Less than or equal to 3.5 143 (59) 229 (64) 75 (54)
3.5-10 34 (14) 43 (12) 29 (21)
10-50 54 (22) 65 (18) 33 (23)
Higher than 50 12 (5) 18 (4) 3 (2)
Platelet count, ×109/L 20 (1-207) 0.32 23 (1-207) 20 (1-137) 0.02
Less than or equal to 40 191 (79) 261 (73) 116 (83)
Higher than 40 52 (21) 94 (27) 24 (17)
Creatinine, mg/dL
Less than or equal to 1.4 231 (98) 0.96 338 (98) 133 (98) 0.99
Higher than 1.4 4 (2) 7 (2) 3 (2)
Coagulopathy
No 54 (22) 0.66 93 (26) 24 (17) 0.03
Yes 188 (78) 259 (74) 116 (83)
Fibrinogen, mg/dL
Less than or equal to 170 132 (57) 0.51 179 (55) 72 (53) 0.76
Higher than 170 99 (43) 147 (45) 63 (47)
Albumin, g/dL
Less than or equal to 3.5 44 (22) 0.83 65 (23) 22 (19) 0.43
Higher than 3.5 152 (78) 221 (77) 93 (81)
Morphologic subtype
Hypergranular 197 (82) 0.89 288 (82) 113 (82) 0.92
Microgranular 44 (18) 62 (18) 25 (18)
PML/RARA isoform
BCR1/BCR2 132 (60) 0.47 186 (60) 64 (51) 0.08
BCR3 87 (40) 124 (40) 62 (49)
Relapse-risk group
Low 45 (19) 0.66 80 (23) 16 (11) 0.02
Intermediate 132 (56) 192 (54) 88 (63)
High 66 (25) 83 (23) 36 (26)
FLT3/ITD
Yes 22 (27) 0.34 33 (23) 12 (19) 0.18
No 60 (73) 112 (77) 51 (81)
Protocol
LPA96 54 (22) 0.49 84 (24) 37 (26) 0.52
LPA99 190 (78) 271 (76) 103 (74)
#P values of the comparison of patients without evaluable karyotype versus patients successfully karyotyped.@ P values of the comparison of patients with t(15;17) alone versus
patients with t(15;17) and additional abnormalities.
not statistically different (Table 3). The complete remission
rate among patients for whom cytogenetic data were
unavailable or inadequate was not different (89%, P=0.26). 
Concerning the subsequent clinical outcome of patients
who achieved complete remission, a total of 53 relapses
were recorded (34 clinical and 19 molecular relapses,
including five with molecular disease persistence after con-
solidation therapy). The overall 5-year relapse-free sur-
vival, disease-free survival, and overall survival rates were
88%, 85%, and 83%, respectively. The corresponding
rates among patients for whom cytogenetic data were
unavailable or inadequate were 85%, 80%, and 76%
(P=0.28, P=0.12, and P=0.08, respectively).
The results of univariate analysis of relapse-free survival
are presented in Table 4. In patients with available kary-
otype, when both protocols LPA96 and LPA99 were con-
sidered together, several variables, such as gender, relapse-
risk score, morphological subtype, and PML/RARA iso-
form, had a statistically significant prognostic value, but
the presence of ACA did not (P=0.10). When analyzed sep-
arately, trisomy 8 was associated with a statistically lower
relapse-free survival compared with the absence of trisomy
8 (78% versus 89%, P=0.03). The relapse-free survival was
lower in relation to the number of chromosomal abnor-
malities detected by conventional karyotyping, but the dif-
ferences were not statistically significant (5-year relapse-
free survival of 93% in patients with a normal karyotype;
89% in patients with t(15;17) alone; 86% in those with one
ACA; 83% with two ACA; and 78% with three or more
ACA; P=0.34) (Table 1). Multivariate analysis identified
relapse-risk score and male gender as the only independent
adverse factors for relapse-free survival (P<0.0001 and
P=0.03, respectively). 
Given the better outcome of the patients treated in the
LPA99 trial compared with those in LPA96, as reported in
previous analyses of this series when patients with and
without available karyotype were included,10,11 we per-
formed an analysis separately by protocol (Table 4). The
J. Cervera et al.
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Table 3. Complete remission, overall survival, disease-free survival and
relapse-free survival rates in patients with and without additional chro-
mosome abnormalities.
t(15;17) alone t(15;17) with
other abnormalities
Outcome (%) (%) P
LPA96 & LPA99 patients
Complete remission 91 90 0.59
5-year overall survival 84 81 0.82
5-year disease-free survival 86 82 0.42
5-year relapse-free survival 90 84 0.10
LPA96 patients
5-year relapse-free survival 81 89 0.33
LPA99 patients
5-year relapse-free survival 92 82 0.01
Table 4. Univariate and multivariate analysis for relapse-free survival in the study population.
LPA96 & LPA99 trials (n=451) LPA96 trial (n=108) LPA99 trial (n=343)
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Characteristic 5-years P P Hazard ratio 5-years P P Hazard ratio 5-years P P Hazard ratio
RFS (%) [95% CI] RFS (%) [95% CI] RFS (%) [95% CI]
Overall 88 84 90
Gender
Male 85 0.02 0.02 0.59 83 0.79 NS 85 0.01 0.01 0.46
[0.38-0.92] [0.27-0.80]
Female 92 85 93
Relapse-risk group*
Low risk 95 <0.001 <0.001 3.60 91 0.01 0.01 2.67 96 <0.001 <0.001 3.49
[2.48-5.22] [1.23-5.79] [2.16-5.65]
Intermediate risk 91 88 92
High risk 74 65 77
Cytogenetics
t(15;17) 90 0.10 NS 81 0.33 NS 92 0.01 NS
t(15;17) + other 84 89 82
Morphological subtype
Hypergranular 90 0.02 NS 89 <0.001 NS 90 0.60 NS
Microgranular 81 56 88
PML/RARAα isoform
BCR1/BCR2 90 0.02 NS 83 0.89 NS 92 0.004 0.02 1.85
[1.02-3.33]
BCR3 82 82 82
PETHEMA LPA trial
LPA96 84 0.09 NS NA NA NA
LPA99 90 NA
RFS: relapse-free survival; NA: not applicable; NS: not significant. *Low risk:WBC ≤10x109/L and platelets >40x109/L; intermediate risk:WBC ≤10x109/L and platelets ≤40x109/L;
high risk:WBC >10x109/L.
univariate analysis showed that the presence of ACA at
diagnosis was significantly associated with lower relapse-
free survival in the LPA99 trial (82% versus 92%, P=0.01)
(Figure 1A), but not in the LPA96 trial (89% versus 81%,
P=0.33). In the LPA99 trial, univariate analysis also showed
a lower relapse-free analysis for patients with trisomy 8
(77% versus 91%, P=0.02) (Figure 1B). Multivariate analysis
showed that in addition to relapse-risk score and male gen-
der, the BCR3 isoform was an independent adverse factor
for relapse-free survival in the LPA99 trial, but the presence
of ACA was not.
Discussion
This study shows that roughly one third of patients with
APL have ACA besides the t(15;17). Among these second-
ary chromosome aberrations, trisomy 8 is by far the most
frequent abnormality, accounting for about one third of the
additional abnormalities. In the context of state-of-the-art
treatment based on a combination of ATRA and anthracy-
cline-based chemotherapy, the presence of ACA, particu-
larly two or more, or of trisomy 8 was associated with
lower platelet counts, a higher relapse-risk score and lower
relapse-free survival. However, multivariate analysis
showed that neither the presence of ACA nor trisomy 8 is
an independent adverse factor for relapse. 
The incidence of ACA in APL has been consistently
reported to be within the range of 26% to 39%,1,4-8,23 tri-
somy 8 being the most frequent abnormality (33% to 53%
of secondary changes). The incidence of ACA and the pro-
portion of trisomy 8 among these abnormalities reported
in the present study, 28% and 36%, respectively, are both
within the ranges reported in the literature. It should be
noted that the prevalence of abn(7q), the most common
abnormality after trisomy 8, is usually in the range from
5% to 8%,4-6,24 and in our study was 5%, but in a recent
study by the German Acute Myeloid Leukemia Study
Group (AMLSG) the prevalence was much higher (27% of
aberrations).8 This German study was, however, based on
a small series of seven patients displaying this abnormality
among only 26 patients with additional changes. 
The relative high frequency of some additional chro-
mosome abnormalities, particularly trisomy 8, may sug-
gest the appropriateness of performing a systematic FISH
analysis including a centromeric probe for chromosome 8
in the diagnostic work-up of patients with APL and per-
haps extending this to the detection of del(7q). As has
been previously reported,14 we found that patients with
t(15;17) not detected by conventional karyotyping had
the same pattern of ACA as patients with conventionally
identified t(15;17), with chromosome 8 abnormalities
being most common. This finding would suggest that the
ACA are important cooperating lesions in the leukemoge-
nesis of APL.
With regards to clinicopathological characteristics, the
association of ACA with low platelet counts, intermediate-
and high-risk disease, and the presence of coagulopathy
found in the present study has not been previously report-
ed as far as we know. At the molecular level, a previous
study found a relationship between the breakpoint at the
BCR3 region and the presence of ACA.4 We did not
demonstrate a statistically significant relation between the
BCR3 isofom and the presence of ACA, but there was a
tendency for the two to be associated (P=0.08). Another
interesting relationship, between ACA and the mutational
status of the FLT3 gene, has been recently suggested.24,25 A
Medical Research Council study24 revealed an inverse rela-
tionship between the frequency of FLT3/ITD and presence
of ACA accompanying t(15;17) analyzed by conventional
cytogenetics. This finding has also been reported by Akagi
et al.25 who analyzed ACA with high-density single-
nucleotide polymorphism microarray to detect copy-num-
ber-neutral loss of heterozygosity. Interestingly, FLT3/ITD
mutations occurred only in the group with no genomic
alterations. In ours series, this mutation occurred in a lower
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A
B
C
Figure 1. Relapse-free survival of patients according to the presence
of additional chromosomal abnormalities in the: (A) LPA96 and
LPA99 trials, (B) LPA96 trial, and (C) LPA99 trial.
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proportion of patients with trisomy 8 (11.5%) than in
those with other ACA (24.3%) or without ACA (22.8%),
but the differences were not statistically significant. 
Although the AMLSG study8 reported that patients
dying during induction therapy had significantly higher ini-
tial white blood cell counts and a higher likelihood of tri-
somy 8 or abn(7q) as ACA, no other study has found such
an association between cytogenetics and induction out-
come. Indeed, we found that patients with ACA had a sim-
ilar induction death rate as those with only the t(15;17).
The association observed in the present study between
ACA and coagulopathy, which is potentially implicated in
an increased risk of induction death,18 could explain in part
the results of the German study. 
As far as we know, only two contradictory studies based
on small series of patients treated in the pre-ATRA era have
previously shown some association between ACA and
relapse.4,5 In 54 patients (44 treated without ATRA), Hiorns
et al.5 found that relapse-free survival was significantly cor-
related with karyotype: patients without ACA and with a
low white blood cell count had a significant advantage in
terms of relapse-free survival in comparison with patients
with other combinations of these factors. In contrast, Slack
et al.4 in a study carried out in 80 patients treated with
chemotherapy alone, found that the presence of a second-
ary chromosome abnormality was associated with a longer
complete remission duration. Our study, based on a large
series of patients treated with ATRA plus anthracycline-
based chemotherapy with prolonged follow-up, does not
confirm a significant relapse-free survival disadvantage in
APL patients with ACA. It should be noted that the
adverse prognostic impact of ACA on relapse observed in
the LPA99 trial, which was not independent of relapse-risk
score, male gender, and BCR3 isoform, was not observed
in the LPA96 trial. Apart from differences in sample size
that could explain a different impact of ACA in the LPA96
and LPA99 trials, it is well known that the efficacy of ther-
apy can have a critical influence on the prognostic signifi-
cance of other variables. In this regard, previous reports
described a lower relapse-free survival in the LPA99
trial,10,11 which may have contributed to altering the prog-
nostic value of many variables, including ACA. We can
also speculate that the adverse impact of ACA on relapse-
free survival in the LPA99 trial, which was revealed by uni-
variate analysis, could be masked in multivariate analysis
because of the association of such abnormalities with
intermediate- and high-risk groups and the BCR3 isoform.
It is conceivable that ACA in general, or some specific
abnormality in particular (e.g., trisomy 8), might have a
role in generating the factors leading to a poorer risk score.
Further studies to confirm and elucidate the relative impor-
tance of these variables are warranted. 
In conclusion, this study confirms that one third of
patients with de novo APL display ACA at diagnosis, tri-
somy 8 being the most frequent abnormality. Patients with
ACA had significantly more coagulopathy, and were less
frequently classified as being at a low-risk of relapse.
Although ACA and trisomy 8 were significantly associated
with lower relapse-free survival, they were not identified
as independent risk factors for relapse, probably because of
their association with relapse-risk score. Until confirma-
tion of this hypothesis, additional therapeutic strategies are
not required in APL patients with ACA, at least in the con-
text of ATRA plus anthracycline monochemotherapy-
based regimens.
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Barcelona: P. Bastida; Hospital Universitario Virgen de la Arrixaca, Murcia: P.
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